Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG) |
| |
Authors: | Köppler Hubert,Fuss Harald,Hurtz Hans J,Knigge Owe,Losem Christoph,Reschke Daniel,Schmitz Stephan,Weide Rudolf,Weiß Johann,Hallek Michael GCLLSG |
| |
Affiliation: | Haematology/Oncology Group Practice, Koblenz, Germany. koeppler@onkologie-Koblenz.de |
| |
Abstract: | The efficacy of bendamustine (50 mg/m2, days 1-3) plus mitoxantrone (10 mg/m2, day 1), every 28 days for up to four courses, was evaluated in a Phase II multicentre trial enrolling 59 patients with relapsed or refractory B-cell chronic lymphocytic leukaemia (CLL). Major toxicities were grade 3/4 leucopenia, thrombocytopenia and infections in 42%, 12% and 12% of patients, respectively. Complete and partial response was achieved in 5/59 and 25/29 patients, respectively (overall response rate, 51%). Median time to progression was 22 months (range 1-49 + ) and median survival 27 months (range 0-49 + ). The combination of bendamustine and mitoxantrone is an active regime in relapsed or refractory CLL. |
| |
Keywords: | CLL leukaemia therapy clinical studies drugs |
本文献已被 PubMed 等数据库收录! |
|